Navigation Links


switched in Medical Technology

Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis

... of 76 patients receiving SIMPONI 50 mg who switched to SIMPONI 100 mg in early escape also achieved ... of 56 patients receiving SIMPONI 50 mg who switched to SIMPONI 100 mg in early escape also achieved ... patients with inadequate arthritis response were switched to SIMPONI 50 mg (patients originally receiving ...

VIDEO from Medialink and the Epilepsy Foundation: New Study Suggests Different Versions of the Same Epilepsy Medication Can Be Harmful

... or sudden death when their medications are switched from one version of an antiepileptic drug (AED) ... worsened for 59 percent of people who had switched from a brand-name to a generic AED, while side ... seizures worsened for 15 percent of those who had switched from a generic to brand AED, while side effects ...

New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting

... percent of patients who completed the study were switched successfully, meeting the primary endpoint. ... was the proportion of patients successfully switched (no worsening of UPDRS II+III >15 percent from ... trial, of which 84.5 percent were successfully switched (with or without dose adaptation) to the ...

After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008

... This study also showed that patients who switched from BYETTA(R) (exenatide) injection after 30 ... either remained on exenatide once weekly or switched from BYETTA to exenatide once weekly for an ... FPG -47+/-3 mg/dL (LS mean+/-SE)]. Patients who switched from BYETTA to exenatide once weekly had further ...

Ustekinumab (CNTO 1275) Phase 3 Data Show Long-Term Improvement Of Chronic Plaque Psoriasis

... with 64 percent and 62 percent of patients switched to placebo (P less than or equal to 0.001 for 45 ... with 37 percent and 38 percent of patients switched to placebo. "The Phase 3 efficacy and safety ... continue treatment with ustekinumab or were switched to placebo. Through week 12 (the ...

Generic Substitutes Less Effective/Safe Than Branded Medications in Treating Lower Urinary Tract Symptoms

... branded alpha blockers or 5-ARIs with an average age of 64, who were switched to generic alternatives by their primary care physician or due to ... function and the prevalence of adverse events. In the men who were switched to generic medications, the IPSS and PVR rates increased and Qmax ...

Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting

... QW and Q2W) and treated for 44 weeks. Subjects receiving PROCRIT TIW were switched to QW dosing after 22 weeks. A dose-adjustment algorithm was used to ... PROCRIT should be permanently discontinued and patients should not be switched to other erythropoietic proteins. -- The safety and efficacy of ...

Sanofi Aventis: People With Type 2 Diabetes Treated With LANTUS(R) and APIDRA(R) Achieved Greater Reductions in A1C Than Those Treated With Pre-mixed Insulin

... One patient (1%) randomized to the LANTUS(R)/APIDRA(R) treatment therapy switched to the pre-mixed insulin therapy, relative to 9 (10%) randomized to pre-mixed switched to the LANTUS(R)/APIDRA(R) treatment therapy. Additional study findings ...

New Data From Head-to-Head Study Confirms Once-Daily Levemir(R) is as Effective as Glargine over a 24-Hour Period in Subjects with Type 2 Diabetes

... state levels of insulin in the body. At the end of the week, subjects were switched to the other insulin. Both insulins were titrated to achieve blood ... need to be adjusted to reduce the risk of hypoglycemia in patients being switched to Levemir from other intermediate or long-acting insulin preparations. ...

Schering-Plough Announces U.S. Filing of Mometasone Furoate/Formoterol Fumarate Combination for the Maintenance Treatment of Asthma

... as the dosage of ASMANEX should be reduced slowly. If you or your child took steroids by mouth and are having them decreased or are being switched to ASMANEX, you should be followed closely by your health care provider and the oral steroids should be reduced slowly. Deaths due to adrenal ...

ASMANEX(R) (Mometasone Furoate Dry Powder Inhaler) Now Approved in Japan for the Treatment of Bronchial Asthma in Adult Patients

... as the dosage of ASMANEX should be reduced slowly. If you or your child took steroids by mouth and are having them decreased or are being switched to ASMANEX, you should be followed closely by your health care provider and the oral steroids should be reduced slowly. Deaths due to adrenal ...

New Small and Medium Sized Enterprises Join TI Pharma by Signing Two New Projects

... are dependent on the formation of new blood vessels. Furthermore, angiogenesis is an early event in the development of tumors, being already switched on in pre-cancerous events and long before visible or clinically relevant tumor mass is present. Schaapveld: "These two features make angiogenesis an ...

AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain

... from oral medication. Patients appear to tolerate the Sufentanil NanoTabs well, and following the end of the 12-hour study period when they were switched to IV PCA morphine, many requested that they be returned to study drug. To me, these patients' requests are as demonstrative as any more quantitative ...

Infant Formula Company Teams With the University of Virginia Pediatrics Department to Conduct Clinical Studies

... M.D., Ph.D., U.Va. Department of Pediatrics and lead researcher on studies involving PBM formulas, it is very common for formula-fed infants to be switched from one formula to another during the first year of life. "It's important to remember that all infant formulas manufactured and sold in the ...

Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk

... randomized to remain on lorcaserin for Year 2 maintained a significantly greater amount of weight loss compared to the lorcaserin patients who switched to placebo at Week 52 in both the ITT-LOCF and per protocol populations. Secondary Endpoint Analysis New data demonstrate that treatment ...

Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders

... measurements, amino acids, and urine collections were completed in a study unit after seven days of on-study treatment. Each patient was then switched to HPN-100 at a dose providing the same amount of the active ingredient (PBA). After seven days of HPN-100 dosing, patients were re-admitted for the ...

Molecular Marker Identifies Normal Stem Cells as Intestinal Tumor Source

... Prominin1 cells generate the covering of the entire small intestine and are therefore the stem cell of this tissue. Next, the researchers switched on cancer-producing machinery in the Prominin1 intestinal stem cells and used a fluorescent tracer to follow the offspring of these cells. Those ...

Observational Study Finds Changes in Medicare Reimbursement for Erythropoiesis-Stimulating Agents Associated With Increased Need for Blood Transfusion

... antibodies. If erythropoietin antibody-mediated anemia is confirmed, PROCRIT should be permanently discontinued and patients should not be switched to other erythropoietic proteins. The safety and efficacy of PROCRIT therapy have not been established in patients with a known history of a ...

Novexel's NXL104/ceftazidime Combination Commences Phase II Clinical Trial in Hospital Patients With Complicated Urinary Tract Infections

... evaluation will be based on the Test of Cure visit five to nine days post-therapy. After at least 4 days of IV antibiotic therapy, patients may be switched to oral ciprofloxacin, if they meet protocol-defined criteria. The total duration of antibiotic therapy for each patient should be 7 to 14 days. The ...

Arpida Completes Enrolment in Phase II "Intravenous-to-Oral" Switch Trial With Oral Iclaprim

... intravenous (IV) vancomycin for the first two days of treatment and were then randomised to either continue to receive IV vancomycin or to be switched to oral iclaprim for eight additional days. A total of 60 patients have been randomised for this study. The key objective of the study is to assess ...

European CHMP Issues Positive Opinion on Cymbalta for the Treatment of Generalised Anxiety Disorder

... the likelihood of relapse in those patients who initially responded to duloxetine and were maintained on treatment for six months compared with those switched to placebo.(7) The most common side effects in these studies included nausea, fatigue, dry mouth, drowsiness, constipation, insomnia, decreased ...

Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes

... better glucose control than glimepiride. Patients previously treated with diet and exercise had greater decreases in HbA1c, as compared to subjects switched from an OAD to liraglutide. In addition, there was significant weight loss, as compared to weight gain with glimepiride, and significantly greater ...

Observational Studies Assess the Potential Impact of Limiting Erythropoiesis-Stimulating Agent Availability on Frequency of Blood Transfusions

... antibodies. If erythropoietin antibody-mediated anemia is confirmed, PROCRIT should be permanently discontinued and patients should not be switched to other erythropoietic proteins. -- The safety and efficacy of PROCRIT therapy have not been established in patients with a known history of a ...

Arpida Enrols First Patients in "Intravenous-to-Oral" Switch Trial With Oral Iclaprim

... from cSSSI receive i.v. vancomycin for the first two days of treatment and are then randomised to either continue to receive i.v. vancomycin or to be switched to oral iclaprim for eight additional days. A total of 60 patients will be randomised for this study. Dr Paul Hadvary, Head of Development of ...

Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration

... Dr. Omar A. Minai of the Cleveland Clinic presented data from an ongoing single-center, 8-week study of treatment satisfaction of PAH patients who switched from epoprostenol (Flolan(R)) to intravenous Remodulin. Rapid switch from Flolan to Remodulin occurred by directly switching the infusion pump ...

Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission

... from the open-label arm of CHARM received their previous open-label regimens [40 mg EOW or every week (EW)]. Patients in the OLE study could be switched to EW dosage for flare or non-response. The results from both HUMIRA doses were pooled for the analyses. About the CHARM Trial The CHARM (Crohn's ...

New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting

... antibodies. If erythropoietin antibody-mediated anemia is confirmed, PROCRIT should be permanently discontinued and patients should not be switched to other erythropoietic proteins. -- The safety and efficacy of PROCRIT therapy have not been established in patients with a known history of a ...

Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings

... antibodies. If erythropoietin antibody-mediated anemia is confirmed, PROCRIT should be permanently discontinued and patients should not be switched to other erythropoietic proteins. -- The safety and efficacy of PROCRIT therapy have not been established in patients with a known history of a ...

Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote

... antibodies. If erythropoietin antibody-mediated anemia is confirmed, PROCRIT should be permanently discontinued and patients should not be switched to other erythropoietic proteins. -- The safety and efficacy of PROCRIT therapy have not been established in patients with a known history of a ...

Totality of Available Data Reaffirms PROCRIT(R) (Epoetin alfa) Is Safe and Effective When Used Appropriately as Labeled to Treat Chemotherapy-Induced Anemia

... antibodies. If erythropoietin antibody-mediated anemia is confirmed, PROCRIT should be permanently discontinued and patients should not be switched to other erythropoietic proteins. -- The safety and efficacy of PROCRIT therapy have not been established in patients with a known history of a ...

Statement from the American Diabetes Association Related to ACCORD Trial Announcement

... less than 6 percent or a standard treatment program with an A1C between 7 percent and 7.9 percent. The intensive participants in ACCORD are now being switched to the standard treatment program because of an increased death rate in the intensive treatment program (14 deaths per 1000 patients per year versus ...

Observational Data Show Transfusion Patterns in Chemotherapy-Induced Anemia Patients Receiving Erythropoiesis-Stimulating Agents

... antibodies. If erythropoietin antibody-mediated anemia is confirmed, PROCRIT should be permanently discontinued and patients should not be switched to other erythropoietic proteins. -- The safety and efficacy of PROCRIT therapy have not been established in patients with a known history of a ...

Research Identifies Need for Improved Understanding of Sickle Cell Disease in Adulthood

... were equally effective at reducing liver iron concentration. In this four-year extension study, all patients stayed on deferasirox (n=132) or were switched to the therapy (n=53). The trial showed that deferasirox demonstrated dose-dependent efficacy in patients with sickle cell disease, with a manageable ...

PROCRIT(R) (Epoetin Alfa) Data to be Presented at American Society of Hematology Annual Meeting

... antibodies. If erythropoietin antibody-mediated anemia is confirmed, PROCRIT should be permanently discontinued and patients should not be switched to other erythropoietic proteins. -- The safety and efficacy of PROCRIT therapy have not been established in patients with a known history of a ...

SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia

... treatment of schizophrenia for 16 weeks (n=197) were randomized and either continued on SEROQUEL XR (n=94; 400-800 mg/day, flexibly dosed) or were switched to placebo (n=103). The primary endpoint was the time from randomization to psychiatric relapse (hospitalization for worsening schizophrenia, ...

New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings

... the placebo or 50 mg group demonstrating less than 20 percent improvement from baseline in both total back pain and morning stiffness measures were switched to either golimumab 50 mg (previously receiving placebo) or golimumab 100 mg (previously receiving golimumab 50 mg). Through week 24, golimumab was ...

New MIRCERA(R) Data Analyses to be Featured at the American Society of Nephrology Annual Meeting

... November 4: 10:00 a.m. - 12:00 p.m. PST. Exhibit Hall, Moscone Center) -- C.E.R.A. maintains hemoglobin in dialysis patients directly switched from epoetin (EPO) without increasing iron therapy requirements. A. Nissenson et al. (F-PO855. November 2: 10:00 a.m. - 12:00 p.m. PDT. ...

Progen Announces PI-88 Phase 2 Lung Cancer Results

... in patients with non small cell lung cancer that have failed platinum based first line therapies is warranted. However, nine patients in the study switched to PI-88 after experiencing toxicity or disease progression with docetaxel monotherapy. The data for this patient group suggests a potential survival ...

Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label

... antibodies. If erythropoietin antibody-mediated anemia is confirmed, PROCRIT should be permanently discontinued and patients should not be switched to other erythropoietic proteins. * The safety and efficacy of PROCRIT therapy have not been established in patients with a known history of a ...

Results from Study Evaluating PROCRIT(R) in Intensive Care Unit Patients Published in New England Journal of Medicine

... antibodies. If erythropoietin antibody-mediated anemia is confirmed, PROCRIT should be permanently discontinued and patients should not be switched to other erythropoietic proteins. -- The safety and efficacy of PROCRIT therapy have not been established in patients with a known history of a ...
Other Contentsdyslexiadyslexiadysmenorrheadysphagiadyspepsiadyspepsiadysenterydysenterydystoniadystonia
(Date:11/25/2009)...firefighters, police officers and ambulance worker...ade Center complex. They battled to save people fr...ors, tackled fires and evacuated as many people as...d 17,000 people. And making their jobs even harder...d workers and their relatives jammed mobile networ...
(Date:11/25/2009)...iversity assistant professors recently received fu...o continue research beneficial to understanding th... Christopher Blackwood, assistant professor in th...rants to support two separate research projects. ,...composer Communities and Functions from the Leaf t...
(Date:11/24/2009)... opening new doors to understanding how sounds ass...f a marine mammal or if they hear it at all. , ...ners that NASA uses to detect flaws in the space s...ng scientists to peek inside the giant head of a w...sional replicas of a whale,s hearing anatomy using...
Breaking Biology News(10 mins):Magic box for mission impossible 2Magic box for mission impossible 3Kent State University professors focus research on the environment with grants totaling $890,000 2Rocket science leads to new whale discovery 2BioInformatics LLC New Report New Media Marketing Channels 3A Creating Effective Online Life Science Promotional Videos 56809 1BioInformatics LLC New Report New Media Marketing Channels 3A Creating Effective Online Life Science Promotional Videos 56809 2BioInformatics LLC New Report New Media Marketing Channels 3A Creating Effective Online Life Science Promotional Videos 56809 3Childrens Hospital Receives Six Year Federal Contract to Study Antibiotic Use in Children With Urinary Tract Infections 4963 1Childrens Hospital Receives Six Year Federal Contract to Study Antibiotic Use in Children With Urinary Tract Infections 4963 2Replication at DNA damage sites highlights Fanconi anemia and breast cancer proteins 56805 1Replication at DNA damage sites highlights Fanconi anemia and breast cancer proteins 56805 2
(Date:11/28/2009)...RNewswire/ -- Get ready for advanced visualizat...ine when Siemens introduces syngo. via(1)...ing of the Radiological Society of North America (...Place (Booth #825, East Building/Lakeside Center, ...ens, new imaging software for multimodality readin...
(Date:11/28/2009)...pirits, recognize signs of depression , ,...eniors, the holiday season can trigger melancholy ... health issues or worry about money problems, acco...help overcome the seasonal blues, the AGS Foundati...: , Get out and socialize or invite family and f...
(Date:11/27/2009)... firm Replikins Ltd. today issued its latest bioch...t shows that the lethality of the virus has droppe...,s current outbreak in the spring of 2009 to resti.... The H1N1 infectivity count, however, remains inc...November 27, 2009 -- Biotech firm Replikins Ltd., ...
(Date:11/27/2009)... 27 Preventing disease ...unately every year, new vaccines are being added t...s boost immunity for the same period of time? And,...d to keep immunity strong? ,, In this month,s...Academy of Pediatrics, Michael Pichichero MD, Dire...
(Date:11/27/2009)...e Holdings has announced that it has become a nati...he largest nonprofit organizations dedicated to ar... Delray Beach, FL (Vocus) No... XCHO), a company specializing in the marketing an...cts, has announced today that is has become a nati...
Breaking Medicine News(10 mins):Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 2Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 3Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 4Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 5Health News:Seniors May Need Help Overcoming Holiday Blues 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 3Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 4Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 5Health News:Why Some Vaccines May Require A Booster 2Health News:Why Some Vaccines May Require A Booster 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4
Other TagsClimateClimateFragmentFragmentFragmentMicroscopicMicroscopicAptamerRetroviralRetroviralPlanktonVietnamOther Tagstaxes 2taxes 3cornea 2infant 2infant 3planned 2planned 3further 2further 3further 4further 5further 6further 7further 8further 9further 10neutralizing 2